Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3 Stomach Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasm Metastasis 1 Muscle Invasive Bladder Cancer 1 Meningioma 1 Lung Neoplasms 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 DLBCL 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Nivolumab 130 Sunitinib 120 pembrolizumab 116 Sorafenib 75 Everolimus 67 cabozantinib 66 Bevacizumab 66 pazopanib 60 Ipilimumab 55 Axitinib 55 aldesleukin 48 Magnetic Resonance Spectroscopy 41 Cyclophosphamide 36 Interleukin-2 33 Radiosurgery 32 Interferon-alpha 32 lenvatinib 31 Specimen Handling 29 temsirolimus 27 atezolizumab 24 belzutifan 21 fludarabine phosphate 20 Gemcitabine 20 avelumab 18 Radiotherapy 18 Interferon alpha-2 17 Biopsy 16 fludarabine 15 durvalumab 15 Paclitaxel 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01793636 2014-06-24

ZEBRA

Queen Mary University of London

Phase 2 Terminated

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡